Red Marrow Dosimetry in Radiopharmaceutical Therapy
Red marrow dosimetry estimates the absorbed dose to the active bone marrow during radiopharmaceutical therapy, splitting it into a self-dose from activity in the marrow and a cross-dose from blood, bone, organs, and the remainder of the body. Because hematologic toxicity often limits how much activity can be safely given, the marrow is treated as a dose-limiting organ, and its absorbed dose links the administered activity to the risk of falling blood counts. 1, 2
Introduction
In radiopharmaceutical therapy (RPT), the question is rarely "did the drug reach the tumor?" alone. It is also "how much dose did the normal tissues absorb, and which one limits the treatment?" For kidney-avid agents, the kidney may set the ceiling. For many other therapies, the red bone marrow is the dose-limiting organ because hematopoietic stem and progenitor cells are radiosensitive and a modest absorbed dose can lower hemoglobin, white cells, and platelets. 1, 4
Red marrow dosimetry is the discipline that turns measured activity over time into an absorbed dose to the marrow. It is harder than organ dosimetry for a solid organ because the marrow has no sharp boundary on a scan, it is distributed through the skeleton, and the radiopharmaceutical may never bind to it directly. The EANM Dosimetry Committee published dedicated guidelines for bone-marrow and whole-body dosimetry precisely because the marrow dose is both clinically important and methodologically delicate. 1
This guide explains what red marrow dosimetry is, how blood-based and image-based methods estimate the marrow dose, how the historical 2 Gy limit fits modern theranostics, and how to align a dosimetry program with regulatory expectations. DRPS supports these calculations as part of its PET/CT and nuclear medicine physics and medical physics consulting services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.
Topic Explanation
What is "red marrow" and why does it get a dose?
The red (active) marrow is the hematopoietic tissue that produces blood cells. In adults it sits mainly in the spongiosa — the trabecular bone cavities of the axial skeleton (vertebrae, pelvis, sternum, ribs, skull) and the proximal ends of the long bones. Yellow (fatty) marrow is largely inactive. Red marrow dosimetry is concerned with the active fraction, because that is the radiosensitive target. 1, 2
The marrow receives dose from several directions at once. Following the Medical Internal Radiation Dose (MIRD) framework, the total red marrow absorbed dose is the sum of a self-dose from activity physically present in the marrow and a cross-dose from activity in neighboring and distant source regions — blood, trabecular bone, major organs, and the remainder of the body. 2
For therapies that build on the same quantitative foundations, see the MIRD schema for internal dosimetry and voxel-based dosimetry for radiopharmaceutical therapy.
Blood as a surrogate for marrow
The central difficulty is that many radiopharmaceuticals do not bind to the marrow at all. For these agents the marrow activity cannot be imaged directly with confidence, so the blood is used as a surrogate: the activity concentration in blood is measured from timed samples, and the marrow activity concentration is related to it through a red marrow-to-blood activity concentration ratio (often written RMBLR). This blood-based approach is appropriate only when the drug does not specifically accumulate in marrow or bone. 1, 2
When the agent, or a radioactive daughter, does localize to bone or marrow — or when skeletal tumor burden is high — the blood surrogate breaks down, and an image-based estimate from a marrow-rich region becomes more defensible. 1, 3
Key Technical Principles
The MIRD red marrow dose equation
The red marrow absorbed dose over the treatment is expressed as a time-integrated activity multiplied by radionuclide- and geometry-specific S-values: 2
Here
Blood-based self-dose
In the blood-based method, the marrow self-contribution is derived from the blood activity concentration, scaled by the red marrow-to-blood ratio. The cumulated activity concentration in marrow is estimated as:
where
A worked activity-to-dose example
The clearest way to see why marrow dose matters is to connect it to a real regimen. In a large Lu-177 DOTATATE cohort, the mean bone marrow absorbed dose was reported as about 67 mGy per GBq of administered activity. For a patient treated with the common fixed schedule of four cycles of 7.4 GBq (a cumulative 29.6 GBq), the estimated marrow dose is: 4
That is not a coincidence. The standard four-cycle regimen lands close to the historical 2 Gy marrow limit, which is one reason the limit remains a familiar reference point even as its validity for Lu-177 is questioned. 4
Comparing the main methods
| Method | Primary data | How marrow activity is estimated | Key assumption | When it is preferred |
|---|---|---|---|---|
| Blood-based | Timed blood samples; often whole-body counts | Blood concentration × red marrow-to-blood ratio | Drug does not specifically bind marrow or bone; blood tracks marrow | Non-marrow-binding agents such as many peptides; thyroid cancer I-131 |
| Image-based (planar) | Conjugate-view planar images over time | Counts in a marrow-rich region (e.g., lumbar vertebrae) via conjugate-view quantification | Chosen region represents active marrow; overlying tissue corrected | Agents with uptake in marrow-rich regions; when blood sampling is impractical 3 |
| Image-based (SPECT/CT) | Quantitative SPECT/CT over time | Calibrated activity in a segmented marrow volume | Accurate attenuation/scatter correction and calibration | Highest quantitative accuracy; heterogeneous or skeletal disease |
| Remainder-of-body / whole-body | Whole-body probe or images | Supports the cross-dose term and whole-body dose | Uniform clearance of non-source activity | As a complement to self-dose estimates 1 |
The numbers and assumptions in the table are representative of published methods, not a substitute for a facility-specific protocol. A defensible calculation documents the sampling schedule, the imaging time points, the quantification method, the S-values and reference anatomy, and the uncertainty budget. 1, 2
Clinical Impact
The 2 Gy limit and where it applies
The widely used 2 Gy absorbed-dose limit to the bone marrow originated in early iodine-131 therapy evaluated with blood-based dosimetry, where keeping the marrow (or blood) dose below roughly 2 Gy was associated with acceptable hematologic toxicity. It is a practical reference value, not a universal hard threshold. 4 For thyroid cancer specifically, the blood-based approach remains a well-established technique — see blood-based dosimetry in I-131 thyroid cancer therapy.
What the Lu-177 data show
Peptide receptor radionuclide therapy with Lu-177 DOTATATE has sharpened the question of how well the 2 Gy limit transfers to newer agents. In one series of 320 patients, grade 3 or 4 hematologic toxicity occurred in about 11%, and the mean marrow dose per administered activity was about 67 mGy/GBq — so a standard four-cycle course delivers a mean marrow dose near 2 Gy, yet severe toxicity was uncommon. The authors concluded that the 2 Gy limit adopted from I-131 does not appear valid for Lu-177 DOTATATE. 4
A separate study developed a planar image-based marrow dosimetry method and found a mean marrow dose of about 0.20 Gy per 7.4 GBq cycle (roughly 0.64 Gy over a full course), with the dose per cycle correlating with drops in hemoglobin, white cells, and platelets. In other words, an image-based estimate tied to the lumbar marrow tracked hematologic response — a correlation that blood-based estimates have not always reproduced for this agent. 3
For the broader theranostic context, see Lu-177 DOTATATE PRRT for neuroendocrine tumors and Lu-177 theranostics dosimetry.
Risk factors beyond the dose number
The marrow dose does not act alone. Reported risk factors for hematologic toxicity after RPT include impaired renal function, a low baseline white blood cell count, extensive tumor mass, high tumor uptake on imaging, and advanced age. Prior chemotherapy has been associated in some analyses and not others. A marrow dose estimate is most useful when interpreted alongside these clinical factors rather than as a single pass/fail number. 4
Practical Optimization Tips
A defensible marrow dosimetry workflow follows a consistent sequence.
1. Choose the method before the first cycle
Decide whether blood-based or image-based dosimetry fits the agent and the patient. Non-marrow-binding peptides may suit blood-based methods; agents with skeletal uptake or patients with bone metastases usually need image-based estimates. 1
2. Standardize the sampling and imaging schedule
Blood-based dosimetry needs timed samples that capture both the early distribution and the later clearance phases. Image-based dosimetry needs multiple post-injection time points to define the time-activity curve. Too few time points is one of the largest sources of error in the time-integrated activity. 1
3. Define the marrow region carefully
For image-based methods, the lumbar vertebrae (commonly L2 to L4) are a frequent surrogate for active marrow. Draw the volume to represent trabecular marrow and exclude skeletal metastases and cortical bone, because including a bony lesion inflates the apparent marrow activity and distorts the dose-toxicity relationship. 3
4. Calibrate and correct quantitatively
Quantitative SPECT/CT requires a calibrated camera (counts to activity), attenuation and scatter correction, and recovery/partial-volume consideration. Planar conjugate-view methods require background and overlap correction. The calibration chain should be documented and traceable. 1, 2
5. Use consistent S-values and state the reference anatomy
Red marrow S-values depend on the radionuclide emissions and the computational phantom. Record which S-values and reference anatomy were used so results can be compared across cycles and, ideally, across centers. 2
6. Report uncertainty
A marrow dose without an uncertainty estimate invites overinterpretation. Propagate the main uncertainties — quantification, time-activity fitting, RMBLR or region selection, and S-values — so the clinician knows how firm the number is. 1
Regulatory Considerations
Red marrow dosimetry sits inside the medical-use framework for byproduct material, even when a drug's approved label specifies a fixed activity. The dosimetry analysis, methods, and assumptions should be documented so they are defensible during internal review or inspection.
Key frameworks to reference:
- 10 CFR Part 35 — Medical Use of Byproduct Material, which governs authorized users, the written directive, and the determination and documentation of the administered dosage for therapy. 5
- 10 CFR Part 20 — Standards for Protection Against Radiation, including the ALARA principle and occupational and public dose limits that frame the overall radiation safety program. 6
- EANM Dosimetry Committee guidelines — methodological guidance for bone-marrow and whole-body dosimetry, including data acquisition and analysis. 1
- MIRD Pamphlet No. 21 — the standardized schema and nomenclature for radiopharmaceutical dosimetry that underpins the dose equation. 2
- FDA prescribing information — the approved administered activity and administration schedule for the specific product (for example, the fixed four-cycle Lu-177 DOTATATE regimen). 7
Agreement States administer their own equivalent medical-use programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must verify which authority issues its license and which written-directive, recordkeeping, and reporting requirements apply. Marrow dosimetry is not a substitute for the written directive or for the recordkeeping and reporting that Part 35 requires; it is a technical input that supports safe, personalized therapy. 5, 6
Facilities building or expanding a theranostics program should connect dosimetry to written procedures, authorized-user and authorized-medical-physicist oversight, radioactive material license support, and RSO program guidance. The international practical guidance for PRRT is a useful reference for program structure. 8
Frequently Asked Questions (FAQs)
What is red marrow dosimetry?
Red marrow dosimetry is the estimation of the absorbed dose to the active (red) bone marrow during radiopharmaceutical therapy. It combines a self-dose from radioactivity in the marrow with a cross-dose from activity in blood, bone, major organs, and the remainder of the body, usually following the MIRD schema. Because hematologic toxicity often limits how much activity can be safely administered, the red marrow is treated as a dose-limiting organ.
Why is the bone marrow the dose-limiting organ in many therapies?
Hematopoietic stem and progenitor cells in the red marrow are radiosensitive, so a modest absorbed dose can lower blood counts. For therapies that are not dominated by kidney dose, the marrow dose often sets the ceiling on administered activity, which is why marrow dosimetry is central to personalized treatment planning.
What is the 2 Gy bone marrow limit and where did it come from?
The commonly cited 2 Gy absorbed-dose limit to the bone marrow comes from early iodine-131 therapy evaluated with blood-based dosimetry. It is a practical threshold associated with acceptable hematologic toxicity, not a universal hard limit, and published data suggest it may not transfer directly to newer agents such as Lu-177 DOTATATE.
What is the difference between blood-based and image-based marrow dosimetry?
Blood-based dosimetry uses timed blood samples (and sometimes whole-body measurements) as a surrogate for marrow activity when the radiopharmaceutical does not bind specifically to marrow. Image-based dosimetry uses quantitative planar or SPECT/CT imaging of a marrow-rich region, such as the lumbar vertebrae, to estimate marrow activity directly. Each method has different assumptions and limitations.
When is blood-based dosimetry not appropriate?
Blood-based dosimetry assumes the radiopharmaceutical does not specifically accumulate in marrow or bone and that blood activity tracks marrow activity. If the agent or its daughters bind to bone or marrow, or if there is extensive skeletal tumor involvement, the blood surrogate can misestimate the marrow dose, and image-based methods may be more appropriate.
Does the FDA label require marrow dosimetry before treatment?
Approved labels for several radiopharmaceutical therapies specify a fixed administered activity and do not require pre-treatment marrow dosimetry. Dosimetry is nonetheless valuable for research, for complex or retreatment cases, and for programs moving toward personalized, dose-optimized therapy, and it should be performed under qualified medical physics oversight.
Which radionuclides and therapies make marrow dosimetry most relevant?
Marrow dosimetry is especially relevant for beta-emitting therapies with a photon component suitable for quantitative imaging, such as Lu-177 DOTATATE and Lu-177 PSMA, and for iodine-131 therapy. Alpha-emitter therapies raise additional microdosimetric questions that standard MIRD marrow dosimetry does not fully capture.
Key Takeaways
- The marrow is often the dose-limiting organ. When kidney dose is not the ceiling, hematologic toxicity usually is, which is why marrow dosimetry drives personalized activity selection. 1, 4
- The dose has two parts. The MIRD red marrow dose is a self-dose from activity in the marrow plus a cross-dose from blood, bone, organs, and the remainder of the body. 2
- Blood is a surrogate, not the target. Blood-based dosimetry works only when the agent does not bind marrow or bone; image-based methods are preferred when it does or when skeletal disease is present. 1, 3
- The 2 Gy limit is historical. It comes from I-131 blood-based dosimetry and may not transfer to Lu-177 DOTATATE, where a standard course delivers a mean marrow dose near 2 Gy with modest severe toxicity. 4
- Image-based marrow dose can track toxicity. A lumbar-vertebrae planar method correlated with falls in hemoglobin, white cells, and platelets. 3
- Document methods and uncertainty. Record the sampling schedule, quantification, S-values, reference anatomy, and uncertainty so results are comparable and defensible. 1, 2
Conclusion
Red marrow dosimetry is where radiopharmaceutical therapy meets its most common limiting toxicity. The marrow has no clean boundary on a scan, it is spread through the skeleton, and the drug may never touch it directly, so the calculation depends on choosing the right surrogate, sampling or imaging carefully, and applying a consistent dose model.
The historical 2 Gy limit remains a useful reference point, but the Lu-177 data make clear that it is not a universal rule, and that an image-based marrow dose tied to the active marrow can be more informative than a blood surrogate for some agents. As theranostics moves toward personalized, dose-optimized treatment, a documented, uncertainty-aware marrow dosimetry workflow — performed under qualified medical physics oversight — is what turns a dose estimate into a defensible clinical decision.
How DRPS Can Help
Diagnostic Radiation Physics Services helps nuclear medicine and theranostics programs build practical, documented dosimetry workflows. This can include method selection, quantitative SPECT/CT calibration review, time-activity curve and uncertainty analysis, PET/CT and nuclear medicine physics support, medical physics consulting, radioactive material license support, and RSO program guidance aligned with NRC and Agreement State requirements.
DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.
A strong dosimetry program makes personalized therapy defensible — connecting the activity administered to the risk the clinician actually cares about.
Related Resources
- The MIRD schema for internal dosimetry
- Voxel-based dosimetry for radiopharmaceutical therapy
- Lu-177 DOTATATE PRRT for neuroendocrine tumors
- Blood-based dosimetry in I-131 thyroid cancer therapy
- Lu-177 theranostics dosimetry
- RPT shielding for Lu-177, Ra-223, and Ac-225
- PET/CT and nuclear medicine physics
- Medical physicist consulting
References
- Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238-1250. doi:10.1007/s00259-010-1422-4. PubMed
- Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry — standardization of nomenclature. J Nucl Med. 2009;50(3):477-484. doi:10.2967/jnumed.108.056036. PubMed
- Svensson J, Rydén T, Hagmarker L, Hemmingsson J, Wängberg B, Bernhardt P. A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Phys. 2016;3(1):21. doi:10.1186/s40658-016-0157-0. PubMed
- Bergsma H, Konijnenberg MW, Kam BLR, et al. Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2016;43(3):453-463. doi:10.1007/s00259-015-3193-4. PubMed
- U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
- U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
- U.S. Food and Drug Administration. Lutathera (lutetium Lu 177 dotatate) prescribing information. accessdata.fda.gov
- Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800-816. doi:10.1007/s00259-012-2330-6. PubMed
- International Commission on Radiological Protection. ICRP Publication 103: The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37(2-4). icrp.org
- Society of Nuclear Medicine and Molecular Imaging. MIRD resources and internal dosimetry committee materials. snmmi.org
Related Articles
-
Lu-177 Theranostics Dosimetry: MIRD and SPECT/CT
Lu-177 dosimetry for Lutathera and Pluvicto: MIRD schema, SPECT/CT workflows, kidney, salivary and lacrimal-gland doses, and fixed vs personalized.
-
Lu-177 Production: Carrier-Added vs n.c.a.
Carrier-added vs non-carrier-added Lu-177: how the production route sets specific activity, the Lu-177m impurity, labeling, and radioactive-waste handling.
-
I-131 Blood Dosimetry in Thyroid Cancer Therapy
Benua-Leeper blood dosimetry for I-131 thyroid cancer therapy: the 2 Gy blood limit, 48-hour retention limits, and how to find the maximum safe activity.